Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Flubendazole reduces emerging Dracunculus medinensis in dogs in Chad: Results from a two-year study.

Created on 26 Sep 2026

Authors

Amy C Dupper, Charles D Mackenzie, Timothy G Geary, Deborah L Elder, Wided Najahi-Missaoui, Christopher A Cleveland, Ellen K Haynes, Michael J Yabsley, Guilherme Gomes Verocai, Macon Overcast, John A Bryan Ii, Fernando Torres-Velez, Métinou Koumétio Sidouin, Bongo Nare Richard Ngandolo, Philip Tchindebet Oaukou, Adam J Weiss, Rebecca Garabed

Published in

PLoS neglected tropical diseases. Volume 20. Issue 9. Pages e0014763. Sep 25, 2026. Epub Sep 25, 2026.

Abstract

Since being targeted for eradication in the 1980s, global human cases of dracunculiasis (Guinea worm disease; GWD) have been reduced by over 99.9% through interventions aimed at interrupting the life cycle of the causative parasite, Dracunculus medinensis. However, the burden of GWD in dogs is higher than in humans and other monitored mammalian host species, threatening eradication of GWD. Expanding on a previous clinical trial of flubendazole (FLBZ) in dogs in Chad, we conducted a cluster-randomized controlled trial in which half of enrolled villages (N = 29) were assigned to receive FLBZ and the other half (N = 27) to receive no treatment. An annual difference-in-differences analysis revealed that treated villages had 59.3% fewer predicted emerging D. medinensis adult females (95% CI: 53.8% fewer to 69.2% fewer) per village per year during the second year of the study compared to control villages. Analyses examining effects of FLBZ monthly, at the individual dog level, and through histopathology of D. medinensis female reproductive morphology, all support the conclusion that FLBZ inhibits embryogenesis and larval development within the uterus of gravid female worms. Together these data are consistent with a hypothesis that although D. medinensis emerged from individually treated dogs, the L1s released from dogs treated with FLBZ exhibited reduced viability, thus reducing the risk of infection in the next mammalian host. This trial builds the body of knowledge about FLBZ's impacts on D. medinensis in the canine host and provides compelling evidence on the effectiveness of FLBZ in reducing the number of emerging D. medinensis in dogs, which can contribute to the eradication of this parasite. However, additional questions remain regarding the formulation, which need to be addressed in future studies before being deployed at scale.

PMID:
42789688
Bibliographic data and abstract were imported from PubMed on 26 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 15
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement